Please use this identifier to cite or link to this item: http://adhlui.com.ui.edu.ng/jspui/handle/123456789/2696
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOgunniyi, A.-
dc.date.accessioned2024-08-15T14:12:56Z-
dc.date.available2024-08-15T14:12:56Z-
dc.date.issued1997-
dc.identifier.citationAfr. J. Med. med. Sci. (1997) 26, 101-103en_US
dc.identifier.issn1116-4077-
dc.identifier.urihttp://adhlui.com.ui.edu.ng/jspui/handle/123456789/2696-
dc.descriptionArticleen_US
dc.description.abstractParkinsonism is the commonest extrapyramidal disorder. The condition arises when the striatonigral dopamine content falls below a critical value. The principle of treatment is dopamine replacement or counteracting the effects of acetylcholine, the neurotransmitter which is in abundance. The choice of drug is determined by availability, cost, and side effects. The most commonly prescribed drugs in developing countries are the anticholinergics, which are the least expensive. The dopamine replacement agents are second-line drugs and it appears as if low doses are effective in improving rigidity, gait abnormality, and postural instability. The use of dopa-agonist drugs is more limited, because of cost and side effects. Surgical management of cases is still in its infancy in developing countries. This review also highlights the more recent modes of management practised mainly in developed countries.en_US
dc.description.sponsorshipCOLLEGE OF MEDICNEen_US
dc.language.isoenen_US
dc.publisherCOLLEGE OF MEDICINEen_US
dc.subjectTreatmenten_US
dc.subjectParkinsonianen_US
dc.subjectSyndromesen_US
dc.subjectExtrapyramidalen_US
dc.titleTreatment of parkinsonian syndromes in developing countriesen_US
dc.typeArticleen_US
Appears in Collections:African Journal of Medicine and Medical Sciences

Files in This Item:
File Description SizeFormat 
Oguniyi_Treatment_1997.pdfArticle6.67 MBAdobe PDFView/Open


Items in COMUI (ADHL) are protected by copyright, with all rights reserved, unless otherwise indicated.